• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Tildrakizumab (MK‐3222), an anti‐interleukin‐23p19 monoclonal antibody, improves psoriasis in a phase IIb randomized placebo‐controlled trial
ConclusionsTildrakizumab had treatment effects that were superior to placebo, maintained for 52 weeks of treatment, and persisted for 20 weeks after cessation. Tildrakizumab was generally safe and well tolerated. These results suggest that IL‐23p19 is a key target for suppressing psoriasis.
Source: British Journal of Dermatology - October 15, 2015 Category: Dermatology Authors: K. Papp, D. Thaçi, K. Reich, E. Riedl, R.G. Langley, J.G. Krueger, A.B. Gottlieb, H. Nakagawa, E.P. Bowman, A. Mehta, Q. Li, Y. Zhou, R. Shames Tags: Clinical Trials Source Type: research

Transient memory impairment and transient global amnesia induced by photodynamic therapy
This article is protected by copyright. All rights reserved.
Source: British Journal of Dermatology - June 30, 2015 Category: Dermatology Authors: M. Reinholz, M.V. Heppt, F. Hoffmann, N. Lummel, T. Ruzicka, P. Lehmann, C. Berking Tags: Case Report Source Type: research

Tildrakizumab (MK‐3222), an Anti‐ IL‐23p19 Monoclonal Antibody, Improves Psoriasis in a Phase 2b Randomized Placebo‐ Controlled Trial
ConclusionsTildrakizumab demonstrated superior efficacy vs. placebo that was maintained up to 52 weeks of treatment and for an additional 20 weeks after cessation of study therapy. Tildrakizumab was generally safe and well tolerated. These results suggest that IL‐23p19 is a key target for suppressing psoriasis. ClinicalTrials Registry # NCT01225731This article is protected by copyright. All rights reserved.
Source: British Journal of Dermatology - June 1, 2015 Category: Dermatology Authors: K. Papp, D. Thaçi, K. Reich, E. Riedl, R.G. Langley, J.G. Krueger, A.B. Gottlieb, H. Nakagawa, E.P. Bowman, A. Mehta, Q. Li, Y. Zhou, R. Shames Tags: Original Article Source Type: research